The Current Ratio as of November 2024 (TTM) for RAPT Therapeutics, Inc. (RAPT) is 9.90

According to RAPT Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 9.90. This represents a change of 22.01% compared to the average of 8.12 of the last 4 quarters.

RAPT Therapeutics, Inc. (RAPT) Historical Current Ratio (quarterly & annually)

How has RAPT Current Ratio performed in the past?

The mean historical Current Ratio of RAPT Therapeutics, Inc. over the last ten years is 13.24. The current 9.90 Current Ratio has changed 7.38% with respect to the historical average. Over the past ten years (40 quarters), RAPT's Current Ratio was at its highest in in the June 2021 quarter at 21.93. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

RAPT Therapeutics, Inc. (RAPT) Current Ratio by Quarter and Year

Discovering the peaks and valleys of RAPT Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

RAPT Therapeutics, Inc. (RAPT) Average Current Ratio

How has RAPT Current Ratio performed in the past?

The current Current Ratio of RAPT Therapeutics, Inc. (RAPT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

RAPT Therapeutics, Inc. (RAPT) Current Ratio vs. Peers

How is RAPT’s Current Ratio compared to its peers?

RAPT Therapeutics, Inc.’s Current Ratio is less than Connect Biopharma Holdings Limited (12.04), less than Tyra Biosciences, Inc. (29.55), greater than Xilio Therapeutics, Inc. (1.67), greater than Mineralys Therapeutics, Inc. (8.55), less than Molecular Partners AG (14.33), greater than AN2 Therapeutics, Inc. (9.75), less than Pharvaris N.V. (19.08), greater than PepGen Inc. (8.47), greater than Monte Rosa Therapeutics, Inc. (6.03), less than Design Therapeutics, Inc. (34.61), less than Werewolf Therapeutics, Inc. (10.10), less than Ikena Oncology, Inc. (15.32), greater than Stoke Therapeutics, Inc. (5.09), greater than Anebulo Pharmaceuticals, Inc. (3.45), less than PMV Pharmaceuticals, Inc. (13.98), less than Eliem Therapeutics, Inc. (60.41), greater than HCW Biologics Inc. (0.07), less than Relay Therapeutics, Inc. (18.42), less than Pliant Therapeutics, Inc. (10.26), greater than Black Diamond Therapeutics, Inc. (5.55), greater than Arvinas, Inc. (4.17),

Build a custom stock screener for RAPT Therapeutics, Inc. (RAPT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like RAPT Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

RAPT Therapeutics, Inc. (RAPT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like RAPT Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.